Article
Single-port uro-oncologic surgery improves patient-reported outcomes
Author(s):
“This study demonstrates the superiority of the SP in patient-reported cosmetic and pain outcomes on short- and long-term follow-up after uro-oncological surgical procedures,” the study authors concluded.
Uro-oncologic surgery using the da Vinci Single-Port (SP) robotic system, compared with the Multi-Port (MP) system, improved patient-reported cosmetic and pain outcomes, according to results presented at the 2022 American Urological Association (AUA) Annual Meeting.1
Luca Morgantini, MD
Luca Morgantini, MD, University of Illinois Chicago, and colleagues aimed to determine patient-reported advantages of cosmetic and psychometric surgical outcomes from the da Vinci SP robotic system—which utilizes a single 25-mm incision—for urological procedures, compared with the MP system, the previous model that utilizes multiple 5- to 22-mm incisions.
In the prospective study, patients who underwent uro-oncologic surgery by 3 urologists at the University of Illinois at Chicago from April 2021 to November 2021 were evaluated. Twenty (n = 77) and 90 days (n = 37) after surgery, patients completed a Patient Scar Assessment Questionnaire (PSAQ), which includes 5 subscales: appearance, symptoms, consciousness, satisfaction with appearance, and satisfaction with symptoms.
At 20 days, 24 patients who underwent surgery with the MP system and 53 who underwent the SP system answered the questionnaire, and 13 and 24, respectively, completed it at 90 days.
Twenty days after surgery with the SP and MP systems, there was a significant difference in the percentage of those taking pain medication (50% vs 21%, respectively; P = .009), appearance (17 vs 14; P < .001), symptoms (10 vs 8; P = .012), and consciousness (11 vs 9; P < .001).
Ninety days after surgery with the SP and MP systems, there was a significant difference in appearance between the 2 groups (14 vs 12; P = .016).
“This study demonstrates the superiority of the SP in patient-reported cosmetic and pain outcomes on short- and long-term follow-up after uro-oncological surgical procedures,” the study authors concluded in their abstract. “Symptomatic and cosmetic advantages are present at the 20-day follow up, with better scar appearance being significant also 90 days after surgery.”
Reference
1. Morgantini L, Del Pino M, Bharadwaj A, et al. A Prospective Study of Single-Port Versus Multi-Port Patient Reported Surgical Outcomes. J Urol. 207(55);5S:e1036. doi:JU.0000000000002669.03.
